Join the 'Palonosetron' group to help and get support from people like you.
Posted 30 Jun 2017 by Drugs.com
FRIDAY, June 30, 2017 – Your friends are excited to ride that monster roller coaster, but just looking at it makes you queasy. Is there anything you can do to quell your motion sickness so you can join in the fun? If you suffer from motion sickness, there are some ways to deal with it, one doctor says, though riding roller coasters isn't likely an activity you'll ever love. Motion sickness can occur in cars, on planes, boats, trains and amusement park rides, and even when sitting too close to a movie theater screen or using a virtual reality device. Motion sickness occurs when the brain gets mixed information. The brain combines input from the eyes with information from the parts of the body touching the ground, and then links that information with the vestibular system in the ears that controls balance. If these things don't match up, motion sickness can occur. "Some people can feel ... Read more
Related support groups: Nausea/Vomiting, Ativan, Lorazepam, Benadryl, Promethazine, Diphenhydramine, Zofran, Phenergan, Meclizine, Reglan, Ondansetron, Marinol, Dramamine, Motion Sickness, Compazine, Metoclopramide, Prochlorperazine, Scopolamine, Benadryl Allergy, Thorazine
Posted 14 Oct 2014 by Drugs.com
October 10, 2014 – The U.S. Food and Drug Administration today approved Akynzeo (netupitant and palonosetron) to treat nausea and vomiting in patients undergoing cancer chemotherapy. Akynzeo is a fixed combination capsule comprised of two drugs. Oral palonosetron, approved in 2008, prevents nausea and vomiting during the acute phase (within the first 24 hours) after the start of cancer chemotherapy. Netupitant, a new drug, prevents nausea and vomiting during both the acute phase and delayed phase (from 25 to 120 hours) after the start of cancer chemotherapy. “Supportive care products, such as Akynzeo, help ease the nausea and vomiting patients may experience as a side effect of cancer chemotherapy,” said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. Akynzeo’s effectiveness was established in two clinical trials ... Read more